News
3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.
Published: 2nd May 2023
The process transfer and GMP supply of the
FGF-1 candidate have been achieved successfully by both companies.
Read more
The Regional Minister for Economic and Business Development Mikel Irujo meets with the management of 3P Biopharmaceuticals and its majority shareholder Keensight Capital.
Published: 23rd March 2023
During the meeting, attendees evaluated 3P's trajectory and its investment plan for the next five years.
Read more
3P Biopharmaceuticals is moving forward with its expansion plan and the adaptation of its facilities.
Published: 9th March 2023
The biotechnology company from Navarra opens its third installation in Noáin.
Read more
3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter.
Published: 1st March 2023
The fermenter adds to 3P's capacity for manufacturing biological medicinal products using microbial technology.
Read more
3P Biopharmaceuticals has a 68% female workforce with a scientific background.
Published: 10th February 2023
On the occasion of the International Day of Women and Girls in Science, the company presents 5 stories of science in feminine.
Read more
3P Biopharmaceuticals among the 500 fastest growing companies in Spain
Published: 19th December 2022
This is the first year the company appears in the ranking established by CEPYME for 500 companies that lead business growth in Spain.
Read more
3P Biopharmaceuticals brings together leading international experts in biomedicine to celebrate its 15th anniversary.
Published: 1st December 2022
The event gathered an audience of more than 150 people and was attended by Juan Cruz Cigudosa, Councillor for University, Innovation, and Digital Transformation.
Read more
BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1
Published: 15th November 2022
3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegenerative diseases such as Amyotrophic Lateral Sclerosis.
Read more
3P Biopharmaceuticals awards the prize for the best Master’s Thesis (TFM)
Published: 3rd October 2022
At the closing of the fifth edition of the Master in Galenic Design and Manufacturing in the Pharmaceutical Industry of the University of Navarra.
Read more